Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
Avid Bioservices, Inc. (NASDAQ:CDMO) will announce its second quarter fiscal year 2023 financial results on December 6, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avid Bioservices, Inc. (NASDAQ:CDMO) will announce its second quarter fiscal year 2023 financial results on December 6, 2022, after market close. A conference call is scheduled for 1:30 PM Pacific Time (4:30 PM Eastern Time) the same day, where senior management will discuss these results and highlight recent corporate developments. Avid specializes in contract development and manufacturing services for the biotechnology and biopharmaceutical sectors, with nearly 30 years of experience in producing biologics.
Positive
- Comprehensive range of CGMP clinical and commercial manufacturing services.
- Nearly 30 years of experience in biologics manufacturing.
Negative
- None.
Details
News Market Reaction – CDMO
The recorded move for CDMO in the trading session of this news was +6.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.